Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.435 EUR | +3.62% | +5.41% | +69.10% |
May. 29 | NFL Biosciences: study with CEA presented at congress | CF |
May. 21 | NFL Biosciences receives positive feedback from the FDA | CF |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 |
---|---|---|---|
Capitalization 1 | 23.63 | 23.63 | - |
Enterprise Value (EV) 1 | 23.63 | 23.43 | 21.03 |
P/E ratio | - | - | - |
Yield | - | - | - |
Capitalization / Revenue | 118 x | - | - |
EV / Revenue | 118 x | - | - |
EV / EBITDA | - | - | - |
EV / FCF | -6.46 x | -4.69 x | -2.73 x |
FCF Yield | -15.5% | -21.3% | -36.6% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 9,705 | 9,705 | - |
Reference price 2 | 2.435 | 2.435 | 2.435 |
Announcement Date | 3/29/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 |
---|---|---|---|
Net sales 1 | 0.2 | - | - |
EBITDA | - | - | - |
EBIT 1 | -4.23 | -4.7 | -7.8 |
Operating Margin | -2,115.1% | - | - |
Earnings before Tax (EBT) | - | - | - |
Net income | - | - | - |
Net margin | - | - | - |
EPS | - | - | - |
Free Cash Flow 1 | -3.3 | -5 | -7.7 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 3/29/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 |
---|---|---|---|
Net Debt 1 | - | - | - |
Net Cash position 1 | 2.3 | 0.2 | 2.6 |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow 1 | -3.3 | -5 | -7.7 |
ROE (net income / shareholders' equity) | - | - | - |
ROA (Net income/ Total Assets) | - | - | - |
Assets | - | - | - |
Book Value Per Share | - | - | - |
Cash Flow per Share 2 | -0.7000 | -0.9000 | -1.500 |
Capex 1 | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 3/29/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+69.10% | 25.63M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ALNFL Stock
- Financials NFL Biosciences